708P - The Empower Pathway: An audit of the first 150 patients. Enhanced personalised care of testicular cancer survivors

Background

Testicular cancer follow-up (FU) protocols prioritise early detection of cancer recurrence, yet there's growing interest in addressing chronic toxicities and providing comprehensive survivorship care. The Empower pathway implements a Personalised Stratified Follow-up (PSFU) pathway led by Advanced Nurse Practitioner (ANP) and General Practitioner (GP); providing comprehensive post-treatment support for testicular cancer survivors. This 1-year pilot project of 150 patients was designed in response to local and national NHS strategy for PSFU.

Methods

Consultation data from the first 150 patients was audited. Patients completing six months of consultant-led clinics post-treatment were eligible (with exclusions). The study evaluated patient and tumour characteristics, mental health problems, prevalence of new conditions, as well as onward GP requests made by the Empower Team.

Results

Baseline patient characteristics are presented in the table below. 88 patients (56%) had a new holistic diagnosis. Examples included hypercholesterolemia (n=53, 35.3%), hypogonadism (n=31, 20.7%;), including 9 clinical and 24 subclinical), obesity (n=17, 11.1%), and vitamin D deficiency (n=7, 4.6%). 4 patients (2.6%) were diagnosed with prediabetes/diabetes, and 3 (2%) had vitamin B12 insufficiency. Thirty-eight patients (24.8%) reported symptoms of anxiety, and 8 (5.2%) reported symptoms of depression. Three internal referrals were made to the adult psychological support service with 9.4% being signposted to local primary care services. 100% of patients had a shared care plan. 0.6% of patients required an onward GP referral request. Table: 708P

Conclusions

The Empower pathway, in conjunction with consultant led clinics, enhances personalised care for testicular cancer survivors by introducing a stratified holistic FU programme. This enables better identification and treatment of holistic needs optimising survivorship outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

RM Partners.

Disclosure

All authors have declared no conflicts of interest.